Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK) inhibitor, through a licensing agreement with South Korea-based biotechnology company Oscotec. The deal marks a strategic move by Agios to expand beyond its existing portfolio and enter the immune thrombocytopenia (ITP) treatment market.
The agreement grants Agios worldwide rights to develop and commercialize cevidoplenib across all indications, with a primary focus on ITP, a rare autoimmune blood disorder characterized by low platelet counts and an elevated risk of bleeding. Financial terms include a $25 million upfront payment to Oscotec, along with potential development, regulatory, and commercial milestone payments that could total up to $140 million. Oscotec will also be eligible to receive royalties on future net sales.
ITP affects an estimated 200,000 people globally, including approximately 90,000 adults in the United States. The disease occurs when the immune system mistakenly attacks and destroys platelets, reducing the blood’s ability to clot properly. Current treatment approaches aim to maintain safe platelet levels and prevent serious bleeding episodes while minimizing long-term treatment-related side effects.
Cevidoplenib is designed to address the underlying immune mechanisms responsible for platelet destruction. By selectively inhibiting SYK, a key signaling protein involved in immune cell activity, the therapy seeks to prevent the autoantibody-driven destruction of platelets that is central to ITP. The drug has also been engineered to overcome some of the tolerability challenges associated with first-generation SYK inhibitors, potentially making it more suitable for long-term use.
The investigational therapy has already received orphan drug designation from the U.S. Food and Drug Administration for the treatment of ITP, highlighting its potential importance for patients with limited treatment options.
Agios’ decision to license the drug is supported by encouraging Phase 2 clinical trial data. The global randomized study evaluated cevidoplenib in adults with persistent or chronic ITP over a 12-week treatment period. Although the trial’s primary endpoint did not achieve statistical significance, researchers observed durable and clinically meaningful platelet responses across several secondary endpoints that align with measures commonly used in pivotal ITP studies.
In addition to demonstrating efficacy signals, cevidoplenib was reported to be generally well tolerated, an important consideration in a chronic disease where patients often require long-term treatment. Based on the available data, Agios plans to advance the drug into Phase 3 development during the first half of 2028, following additional chemistry, manufacturing, and controls work.
Brian Goff, Chief Executive Officer of Agios, described cevidoplenib as a promising next-generation therapy with the potential to become a best-in-class treatment for ITP. He said the licensing agreement aligns with the company’s strategy of expanding and diversifying its rare hematology portfolio while remaining focused on areas where significant unmet medical needs persist.
For Oscotec, the agreement provides a pathway to further development of the drug through an established rare disease company while retaining future opportunities. The company has secured an option to obtain exclusive development and commercialization rights in South Korea after Phase 3 trial results become available.
The transaction reflects growing interest in autoimmune blood disorders, where demand remains high for treatments that offer durable efficacy with improved safety profiles. If future clinical studies confirm its potential, cevidoplenib could emerge as an important new treatment option for patients living with immune thrombocytopenia and potentially other autoimmune conditions.
With the addition of cevidoplenib, Agios continues to broaden its pipeline and reinforce its commitment to developing innovative therapies for patients affected by rare diseases.